CytoImmune Therapeutics | Wells Fargo Healthcare Conference

CytoImmune Therapeutics, Inc. CMO Michael Caligiuiri, MD to Present at a KOL Webinar on Human Natural Killer (NK) Cell Immunotherapy
July 16, 2021
CytoImmune Not Affected by The Recent Challenges in Allogeneic CAR T Cell Engineering
October 17, 2021

Join the CytoImmune Therapeutics | Wells Fargo Healthcare Conference

CytoImmune Therapeutics | Wells Fargo Healthcare Conference Session:

September, 2021

About CytoImmune Therapeutics, Inc.

CytoImmune Therapeutics is a clinical-stage biotechnology company founded in 2017. It is focused on developing a portfolio of natural killer (NK) immunotherapies designed to utilize the power of a patient’s own immune system to eliminate cancer cells. CytoImmune is moving towards filing the Investigational New Drug (IND) applications for novel immunotherapy programs in hematological and solid malignancies.

Contact:

Name: Alice Mior
Phone: +57 312 8113601
Email: alice@publicize.co

SOURCE: CytoImmune Therapeutics